Aktieanalys

Herantis Pharma: Directed issue completed - Redeye

Redeye Publicerad: 06 Dec 2023 08:41

Redeye endorses the recent news that Herantis has completed a directed issue of EUR4.5m at a price of EUR1.4 per share, to both existing and new shareholders, including the EIC fund (European Innovation Council). This should extend the company’s runway further (at least into 2025). The issue was close to our estimates (EUR5m at EUR1.35 per share) and we thus make no immediate changes to our valuation. We will soon return with a research update to further discuss the recent progress in the company, most notably the transformative phase I data.

Länk till analysen i sin helhet: https://www.redeye.se/research/965995/herantis-pharma-directed-issue-completed?utm_source=finwire&utm_medium=RSS

Nyheter om Herantis Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!